256 results about "Guanine" patented technology

The invention discloses an information storage method based on DNA (deoxyribonucleic acid) coding, which comprises the following steps: converting digital information to be stored into a quaternary code, converting the quaternary code into a DNA sequence consisting of adenine A, cytosine C, guanine G and thymine T according to a preset mapping rule, and expressing an additional information dimension by using a chemical modification state of a nucleotide pair; inserting error detection and correction codes in the DNA sequence every a predetermined number of basic group positions, segmenting the encoded DNA sequence into a plurality of fragments with the length of 100-150bp, and adding a specific recognition sequence and an index marker at two ends of each fragment; a reversible thermosensitive response DNA nanostructure is used as a carrier, DNA fragments are selectively combined to the carrier, and hierarchical storage and rapid retrieval of information are realized through a temperature gradient control system; the DNA storage information density can be remarkably improved, the service life of DNA storage can be remarkably prolonged, and a novel technical path is provided for large-scale, long-term and safe molecular information storage.

The invention provides a perovskite solar cell, a preparation method thereof and a photovoltaic module. The perovskite solar cell comprises a first electrode, a hole transport layer, a perovskite layer, an electron transport layer and a second electrode which are stacked in sequence. The material of the hole transport layer comprises a biomolecular material which is fixed on a self-assembly monomolecular layer material through an intermolecular force, and the biomolecular material comprises one or more of guanine, adenine, thymine, uracil, cytosine, hydroxymethylcytosine, xanthine, hypoxanthine, 6-mercaptopurine and corrin. According to the perovskite cell provided by the invention, the biomolecular material with a plurality of nitrogen heterocyclic structures and amino groups is added to generate multipoint hydrogen-bond interaction and pi-pi accumulation with the tail end of the SAM, so that the orderliness of molecular arrangement is improved, and the dipole direction and strength of the whole interface are regulated and controlled; and a coordination bond or hydrogen bond network is formed by the coordination compound and uncoordinated cations or anions in perovskite, so that interface defects are effectively passivated, and the thermal stability and the humid and hot life of a device are enhanced.

The present invention relates to an RNA capping enzyme comprising or consisting of an amino acid sequence having high identity with any of the sequences of SEQ ID NO: 1-28, which can be expressed in vitro, in human cells, in mouse cells or in yeast cells, and which has the activities of RNA 5 '-triphosphatase (RT), guanylate transferase (GT) and RNA guine-N7 methyltransferase (RNMT) at the same time. The invention also relates to a mutant obtained by carrying out substitution, addition and / or deletion of amino acid on any sequence in SEQ ID NO: 1-28, a nucleotide sequence for coding the capping enzyme and / or the mutant thereof, and an expression construct or a host cell containing the nucleotide sequence. The invention also relates to a composition comprising the capping enzyme as well as a method and a reaction system for capping RNA by using the capping enzyme, a mutant or a composition thereof.

The invention belongs to the technical field of genetic engineering, and particularly relates to a method for regulating and controlling production of human milk oligosaccharide through membrane protein. The method is realized by inactivating a membrane protein YgfX coding gene on a production strain. According to the human milk oligosaccharide production strain obtained in the mode that the membrane protein YgfX is inactivated after the coding gene of the membrane protein YgfX is knocked out or deleted from a 192nd guanine base through a gene editing technology, the human milk oligosaccharide production capacity of the human milk oligosaccharide production strain is obviously improved compared with that before gene editing, the yields of LNTII, LNnT, LNT, 3 '-SL and 6'-SL are improved by about 40%, 125%, 46%, 32% and 47% respectively, the effect is remarkable, and the human milk oligosaccharide production strain has a good application prospect. And a new method and thought are provided for widening the production way of the human milk oligosaccharide.

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The invention comprises a process for the production of a linear P-linked oligonucleotide bearing an alkyl phosphonate group at 5′-terminus of the formula Iwherein R1 is a C1-4-alkyl group, R2 is fluoro, hydroxyl or C1-4-alkoxy, X is sulfur or oxygen, the term Nucleobase stands for an optionally modified adenine, cytosine, guanine or uracil and the term oligo strand stands for the remaining P-linked oligo nucleotide strand, and wherein the oligo strand comprises at least one uracil nucleobase.The process is performed under conditions that the level of alkyl transfer impurities and the level of cyanoethyl (CNET) impurities in the linear P-linked oligonucleotide of formula I, is substantially reduced.

Embodiments are directed to N3-kethoxal reagents and derivatives thereof, and related methods that allow fast and reversible labeling of single-stranded nucleic acids in live cells. By way of example, one aspect is directed to a process for reversible labeling of single-stranded guanine bases in live cells, which results in an effective in vivo method for transcriptome-wide RNA secondary structure mapping and RNA G-quadruplex prediction.

The present invention is directed to substituted 1-(1H-imidazol-1-yl)-3-methyl-2- phenylbutan-2-ol and 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phenylethan-1-ol compounds useful as agonists of 8-oxo-guanine DNA glycosylase (OGG1) in humans, as well as pharmaceutical compositions comprising them and methods of their use in treating diseases, including metabolic syndrome, obesity, fatty liver disease, dyslipidemia, insulin resistance, neurodegenerative disorders and cancers.

The invention discloses a synthesis method of 2 '-fluoro-2'-deoxyguanosine. According to the method, thymine nucleoside phosphorylase and purine nucleoside phosphorylase are used as biocatalysts, and 2 '-fluoro-2'-deoxyuridine and guanine are used as substrates to synthesize the 2 '-fluoro-2'-deoxyguanosine. Compared with a chemical method, the production cost is greatly reduced; meanwhile, the synthesis method can effectively solve the problem that the product is difficult to separate.

It is unequivocal that to facilitate targeted antimicrobial prescribing practices and to help reduce the increasing global burden of antibiotic resistance, there is an urgent need for the development of novel and truly rapid (less than or equal to 1 hour) AST platforms. A 785 nm SERS based methodology is described that results in accurate MIC determinations for all tested strain / antibiotic pairs following a 30 minute drug incubation period. The time for an SERS AST result is -1 hour. The SERS-AST method works for both Gram positive and Gram negative species and for all primary mechanisms of antibiotic activity. Agreement with 24 hour growth determined MICs is obtained for both bactericidal and bacteriostatic antibiotics although different patterns of dose dependent SERS intensities characterize these two types of antibiotics. Bacterial SERS spectra due to secreted purine nucleotide degradation products (principally adenine, guanine, xanthine and hypoxanthine).

Provided herein are methods of separating molecular species of a guanine-rich oligonucleotide from a mixture of molecular species, wherein at least one molecular species of the mixture is a quadruplex formed from the guanine-rich oligonucleotide. In exemplary embodiments, the methods comprise (a) applying the mixture to a chromatographic matrix comprising a hydrophobic ligand, wherein said hydrophobic ligand comprises C4 to C8 alkyl chains, wherein molecular species bind to the hydrophobic ligand and (b) applying a mobile phase which comprises a gradient of acetate and a gradient of acetonitrile but no cationic ion pairing agent to the chromatographic matrix to elute molecular species of the guanine-rich oligonucleotide. In exemplary aspects, the guamne-rich oligonucleotide elutes in a first set of elution fractions and a quadruplex formed from the guanine-rich oligonucleotide elutes in a second set of elution fractions.

The invention discloses an application of an IMPDH2 inhibitor in preventing or treating inflammation. The limonin compound provided by the invention can be combined with and degrade human inosine-5 '-monophosphate dehydrogenase 2 (IMPDH2), inhibit synthesis of guanine in cells and inhibit activation of an NF-kappa B signal channel, and can be used as an IMPDH2 inhibitor; the IMPDH2 inhibitor also has a relatively good prevention or treatment effect on inflammation. Compared with the existing IMPDH2 inhibitor, the limonin compound provided by the invention can degrade IMPDH2 enzyme, and has better inhibitory activity and stronger activity of inhibiting inflammatory factors.

The present invention relates to certain compounds that function as inhibitors of enzymes which binds guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP) or 5' guanosine triphosphate (GTP) capped RNA, such as enzymes which comprise a RNA cap Guanine N-7 methyl transferase. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of viral infections, as well as other diseases or conditions in which activity of such enzymes is implicated. (Formula (I)

The invention relates to lactobacillus reuteri SAU-R-8 which is derived from Tibet naturally-fermented sour yak milk and is used for producing exopolysaccharides and application of the lactobacillus reuteri SAU-R-8 in reducing uric acid, and belongs to the technical field of microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30373, and the preservation date is April 19, 2024. The lactobacillus reuteri SAU-R-8 provided by the invention is screened from yak yogurt naturally fermented from herdsmen in the Sankarst region of Tibet, the yield of exopolysaccharides in an MRS culture medium reaches 318.57 mg / L, nucleoside substances such as inosine and guanosine can be efficiently degraded, purine substances such as guanine can be efficiently absorbed, the activity of xanthine oxidase can be inhibited, and the lactobacillus reuteri SAU-R-8 can be used for preparing the yak yogurt. The method can be further applied to product development for relieving or treating hyperuricemia.

The invention discloses a preparation method and application of a high-load copper monatomic catalyst, copper nitrate trihydrate and small biological molecule guanine are used as raw materials, and a series of copper monatomic catalysts are directly synthesized through a self-assembly and high-temperature carbonization method. The synthesis process is simple to operate, low in manufacturing cost and high in sustainability. The obtained material has curled two-dimensional morphology, high nitrogen content (-30 at%) and high metal loading capacity (the highest copper content can reach 33.2 wt%). The synthesized catalyst has excellent catalytic activity in a benzene hydroxylation reaction.

Disclosed herein include methods, compositions, and kits suitable for use in capturing lineage relationships in dividing cell populations. Disclosed herein include compact phylogenetic recording systems for high resolution lineage reconstruction over long time scales. In some embodiments, the system comprises one or more hypercascade array(s) each comprising p hypercascade units, n layer guide RNAs, and an editor. In some embodiments, the system comprises one or more target array(s) comprising n editable target sites, n guide RNAs gRNAs, and a base editor capable of adenine (A)-to-guanine (G) base editing.

The invention provides a plasmid for purine base mutation in blue-green algae and a preparation method and application thereof, and belongs to the field of bioengineering, the plasmid provided by the invention is named as pCyABE, the plasmid comprises a TadA-nCas9 fusion protein expression cassette and an sgRNA expression cassette, the nucleotide sequence of the TadA-nCas9 fusion protein expression cassette is shown as SEQ ID No.2, the nucleotide sequence of the sgRNA expression cassette is shown as SEQ ID No.2, and the nucleotide sequence of the sgRNA expression cassette is shown as SEQ ID No.2. The nucleotide sequence of the sgRNA expression cassette is as shown in SEQ ID No. 3. The plasmid provided by the invention is particularly suitable for mutation of adenine at any site on a blue-green algae genome into guanine, realizes fixed-point editing of the gene, has the advantages of high editing efficiency and low off-target rate, and has important significance on physiological property research and industrial application of blue-green algae.

The present disclosure relates to a modified 5'UTR derived from an alphavirus, such as the Venezuelan equine encephalitis virus (VEEV) wild-type 5'UTR sequence of SEQ ID NO 1 modified at least by a first nucleotide insertion, such as ribonucleotide insertion, between position 3 and position 4 of the corresponding wild-type 5'UTR sequence of SEQ ID NO 1, wherein the first nucleotide insertion is preferably guanine, adenine or uracil.

The invention discloses a preparation method of a high-loading-capacity iron diatom catalyst, which is characterized in that iron nitrate nonahydrate and small biological molecule guanine are used as raw materials, and the iron diatom catalyst is directly synthesized through self-assembly and high-temperature pyrolysis methods. The synthesis process is simple to operate, low in manufacturing cost and high in sustainability, the obtained material has curled two-dimensional morphology, high nitrogen content (22-32 at%) and metal loading capacity (the highest iron content can reach 9.7 wt%), and the conversion rate of 92.3% and the selectivity of 96.2% can be achieved in the reaction for preparing phenol through selective oxidation of benzene.

The present invention discloses an application of an IMPDH2 inhibitor in preventing or treating inflammation. The limonoid compound provided by the present invention can bind to and degrade human inosine-5'-monophosphate dehydrogenase 2 (IMPDH2), inhibit the synthesis of intracellular guanine, inhibit the activation of the NF-κB signaling pathway, and can be used as an IMPDH2 inhibitor; the IMPDH2 inhibitor also has a good preventive or therapeutic effect on inflammation. Compared with existing IMPDH2 inhibitors, the limonoid compound provided by the present invention can degrade the IMPDH2 enzyme, has better inhibitory activity, and has stronger activity in inhibiting inflammatory factors.

The present invention provides technology for inhibiting or suppressing proliferation of cells. Disclosed herein is a double-stranded RNA that has a first strand and a second strand which is complementary to the first strand, wherein the first strand has a main sequence which comprises 19-23 bases and in which a base at the 5'-end is guanine (G) or cytosine (C) and an additional sequence which comprises 2-4 bases and which is added to the 3'-end side of the main sequence. The main sequence is a portion of a base sequence that encodes semaphorin-3A, the portion including at least a portion of a base sequence that encodes a signal peptide region of the semaphorin-3A.

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and / or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I

The invention relates to the technical field of bioengineering, in particular to an AimA mutant as well as a construction method and application thereof. It is found for the first time that the activity of glutamic acid / serine transporter is weakened, and the nucleoside production capacity of microorganisms can be improved. Based on this, the present invention provides a modified microorganism in which the glutamic acid / serine transporter activity is reduced or lost as compared to an unmodified microorganism, and the nucleoside production capacity of the modified microorganism is enhanced as compared to the unmodified microorganism, and more specifically, the modified microorganism has a reduced or lost glutamic acid / serine transporter activity as compared to the unmodified microorganism. The modified bacillus subtilis or bacillus amyloliquefaciens provided by the invention can generate guanine nucleoside or hypoxanthine nucleoside with high efficiency and high speed.

The present invention relates to the field of data storage, and discloses a DNA-based dynamic balancing system, a data storage method, and a decoding method. During the process of encoding the first data to obtain a DNA molecular chain, various constraints are added to the first address and the second address, enabling the encoded data to be read efficiently and accurately. For example, the Hamming distance between the first address and the second address is greater than or equal to half of the length of the first address, reducing the possibility of address selection errors during reading; the prefix of the first address is different from the prefix of the second address and the suffix of the second address, avoiding the possibility of matching errors during the reading process; the content of guanine and cytosine in the prefix of each primer accounts for a preset ratio of the total content of guanine, cytosine, adenine, and thymine contained in the primer, resulting in high accuracy when sequencing is required to read the encoded data in advance.

Described herein are methods of modifying or editing a target nucleic acid such as methods that edit adenine to cytosine, thymine, or guanine. Compositions and systems for modifying or editing a target nucleic acid are also described. Methods, compositions and systems described herein may be used for generating allelic diversity.

The present disclosure provides for a method of treating fetal growth restriction in a fetus comprising obtaining a blood sample from a pregnant subject; isolating cell-free fetal DNA from the blood sample; testing the cell-free fetal DNA for a first DNA methylation level of 0.5800 or less in a group of genes, wherein the group of genes comprises the genes of any one of Tables 19-21, wherein the first DNA methylation level is calculated via an average of all differentially methylated islands of cytosine and guanine dinucleotides separated by only one phosphate in the 5' to 3' direction (5'-C-phosphate-G-3') (CpGIs) in differentially methylated regions (DMRs); and when the first DNA methylation level is 0.5800 or less, selecting a treatment from the following: monitoring the fetus during pregnancy of the pregnant subject, tracking movements of the fetus, admitting the pregnant subject to a hospital prior to going into labor, inducing early delivery of the fetus, performing an emergency Cesarean section on the pregnant subject, administering corticosteroids to the pregnant subject, or administering corticosteroids to the fetus upon birth. Other related methods are disclosed herein.

The present invention relates to a composition for base editing of plant organelle DNA and, in particular, to a composition and editing method for editing adenine of plant organelle DNA into guanine.

The present invention discloses an information storage method based on DNA coding. The method comprises the following steps: converting digital information to be stored into a quaternary code, and converting the quaternary code into a DNA sequence consisting of adenine A, cytosine C, guanine G, and thymine T according to a preset mapping rule, and using the chemical modification state of the nucleotide pairs to represent an additional information dimension; inserting error detection and correction codes at every predetermined number of base positions in the DNA sequence, dividing the encoded DNA sequence into multiple fragments of 100-150 bp in length, and adding specific recognition sequences and index markers at both ends of each fragment; utilizing a reversibly thermoresponsive DNA nanostructure as a carrier, selectively binding the DNA fragments to the carrier, and realizing hierarchical storage and rapid retrieval of information through a temperature gradient control system; the present invention can significantly improve the information density and lifespan of DNA storage, and provides a new technical path for large-scale, long-term, and secure molecular information storage.

The invention discloses a preparation method of 6-phenyl-2, 3, 4, 5- The invention discloses a 2, 2 '-bipyridine platinum (II)-guanine N-heterocyclic carbene complex and a preparation method and application thereof, and particularly relates to the complex shown in the specification, the complex has dual inhibitory activity on tumor cells and tumor stem cells at the same time, the problem of platinum drug resistance caused by the tumor stem cells, glutathione and other proteins can be solved, and the drug resistance of the tumor cells and the glutathione can be improved. The compound can be used for preparing drugs for treating various malignant tumors, especially drugs for treating malignant tumors resistant to existing chemotherapeutic drugs. The preparation method is simple and easy to operate. In addition, the 6-phenyl-2, 2 '-bipyridine ligand disclosed by the invention contains carbon anions with relatively strong electron donating ability, and compared with a terpyridine ligand, the 6-phenyl-2, 2'-bipyridine ligand disclosed by the invention can further stabilize a metal ion center, so that the ability of resisting GSH interference is improved, and better stability is shown.

The invention relates to a pharmaceutical intermediate (S)-9-(2, 3-di-O-acetyl propyl)-N2-acetyl guanine and a synthesis method thereof.In the synthesis method, a compound 2 serves as a starting material, sodium acetate, acetic acid and acetic anhydride are added, reaction, concentration and column chromatography purification are performed at the temperature of 110-130 DEG C, and the target product (S)-9-(2, 3-di-O-acetyl propyl)-N2-acetyl guanine is obtained. The invention relates to 2, 3-di-O-acetyl propyl)-N2-acetyl guanine. The invention discloses a novel medical intermediate and designs a feasible synthesis process, through the synergistic effect of all reagents, the reaction can be stabilized under mild conditions, side reactions are effectively avoided, the purity and stability of the product are ensured, and a foundation is laid for popularization of new drugs.